#ASCO20 Here's a look at Boehringer's first-in-human Phase 1 clinical trial of its pan-KRAS inhibitor (BI 1701963). @Boehringer

3 patients have been treated as of 02/11/20. Primary completion data is stated as Feb '21.

Trial link: https://t.co/8aWoWahkFn

$AMGN $MRTX $JNJ $LLY https://t.co/dVNrXIOaUB